Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRUST: Bintrafusp alfa and doxorubicin in advanced soft tissue sarcoma
2023-509497-30-00Phase 2Authorised
- Sponsor
- Institut Bergonié
- Start
- Oct 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in soft tissue sarcoma (STS) comparing Bintrafusp alfa + doxorubicin with Doxorubicin alone (2 arms). Primary endpoint: 6-month progression-free rate. Planned start Oct 2024; status: authorised.
02
Drugs
bintrafusp alfadoxorubicin
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on 2023-509497-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509497-30-00.